Bucillamine
- Generic Name
- Bucillamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H13NO3S2
- CAS Number
- 65002-17-7
- Unique Ingredient Identifier
- R80LRA5WTF
- Background
Bucillamine has been used in trials studying the treatment and prevention of Gout and Rheumatoid Arthritis.
- Associated Conditions
- -
- Associated Therapies
- -
Bucillamine in Treatment of Patients With COVID-19
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 713
- Registration Number
- NCT04504734
- Locations
- πΊπΈ
Sweet Hope Research Specialty Inc, Hialeah, Florida, United States
πΊπΈColumbus Clinical Services, Miami, Florida, United States
πΊπΈEntrust Clinical Research, Kendall, Florida, United States
Bucillamine Phase 2 Trial in Patients With Cystinuria
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02942420
- Locations
- πΊπΈ
New York University School of Medicine, New York, New York, United States
πΊπΈOmega Medical Research, Warwick, Rhode Island, United States
πΊπΈUniversity of Wisconsin School of Medicane and Public Health, Madison, Wisconsin, United States
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
- Conditions
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 91
- Registration Number
- NCT02373202
- Locations
- π―π΅
Investigational Site Number 392039, Fukuoka-Shi, Japan
π―π΅Investigational Site Number 392006, Sasebo-Shi, Japan
π―π΅Investigational Site Number 392023, Takaoka-Shi, Japan
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT02330796
- Locations
- πΊπΈ
Texas Physicians Research Medical Group, Arlington, Texas, United States
πΊπΈWest Coast Research, San Roman, California, United States
πΊπΈSun Research Institute, San Antonio, Texas, United States
Bucillamine Study of Holding Remission After Infliximab Dose-off
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2011-01-05
- Lead Sponsor
- Saitama Medical University
- Target Recruit Count
- 40
- Registration Number
- NCT00716248
- Locations
- π―π΅
Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.